AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB) ('Anebulo'), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication ('ACI'), today announced that Richie Cunningham has been appointed as Anebulo’s Chief Executive Officer, replacing Simon Allen..

德克萨斯州奥斯汀-（BUSINESS WIRE）-Anebulo Pharmaceuticals，Inc。（纳斯达克股票代码：ANEB）（'Anebulo'），一家临床阶段生物制药公司，为患有急性大麻素中毒（'ACI'）的人开发新的解决方案，今天宣布Richie Cunningham已被任命为Anebulo的首席执行官，取代Simon Allen。。

“Anebulo has positioned ANEB-001 for success and I look forward to working with the leadership team and board of directors to achieve Anebulo’s strategic short- and long-term objectives. I am excited about the prospects of making a positive impact in the lives of patients and enhancing the value for all shareholders,” said Mr.

“Anebulo已经成功定位ANEB-001，我期待与领导团队和董事会合作实现Anebulo的战略短期和长期目标。我对在生活中产生积极影响的前景感到兴奋。患者和提高所有股东的价值，“先生说。

Cunningham..

坎宁安。。

'We are fortunate to hire an individual with Mr. Cunningham’s breadth of experience in emerging biotech companies. His leadership and expertise in the biopharmaceutical industry will be valuable as Anebulo prepares for phase 3 development of ANEB-001,' said Joseph F. Lawler, Founder and Chairman.

“我们很幸运能聘请坎宁安先生在新兴生物技术公司拥有丰富经验的个人。创始人兼主席约瑟夫·劳勒（Joseph F.Lawler）说，随着Anebulo为ANEB-001的第三阶段开发做准备，他在生物制药行业的领导和专业知识将非常有价值。

Mr. Cunningham has more than 20 years of successful leadership experience spanning from pre-IND drug discovery through the commercialization and launch of over a dozen therapies. He brings to Anebulo an in-depth understanding of maximizing therapeutic lifecycles, enhancing efficiencies and outcomes in biotech business models, and most importantly a commitment to a values-driven culture..

坎宁安先生拥有超过20年的成功领导经验，从IND前药物发现到商业化和推出十几种疗法。他向Anebulo深入了解最大化治疗生命周期，提高生物技术商业模式的效率和成果，最重要的是对价值驱动文化的承诺。。

Most recently, Mr. Cunningham served as CEO at Tyme where he led the company through a merger with Syros Pharmaceuticals. Prior to Tyme, he was CEO at Icagen, leading the company through two transformational acquisitions. While CEO at Icagen, he oversaw the successful negotiation and execution of multiple licensing deals with Roche, Sanofi and the Cystic Fibrosis Foundation.

最近，坎宁安先生担任Tyme的首席执行官，在那里他通过与Syros制药公司的合并领导该公司。在Tyme之前，他曾担任Icagen的首席执行官，通过两次转型收购领导该公司。在Icagen担任首席执行官时，他负责与罗氏，赛诺菲和囊性纤维化基金会成功谈判和执行多项许可协议。

Prior to joining Icagen, Mr. Cunningham was an executive with Boehringer Ingelheim, where he held a variety of strategic and operational roles, including the launch of multiple products at Boehringer Ingelheim..

在加入Icagen之前，Cunningham先生是勃林格殷格翰的高管，在那里他担任各种战略和运营角色，包括在勃林格殷格翰推出多种产品。。

In addition, Mr. Cunningham excelled in the National Football League, holding All-Pro honors for the Dallas Cowboys. His career in the NFL spanned from 1994 until his retirement in 2002.

此外，坎宁安先生在国家足球联盟中表现出色，为达拉斯的男孩们持有所有荣誉。他在NFL的职业生涯从1994年到2002年退休。

About Anebulo Pharmaceuticals, Inc.

关于Anebulo制药公司。

Anebulo Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse disorder. Its lead product candidate, ANEB-001, has completed dosing in a Phase 2 clinical trial (www.clinicaltrials.gov/ct2/show/NCT05282797) evaluating its utility in blocking and reversing the negative effects of acute cannabinoid intoxication.

Anebulo Pharmaceuticals，Inc。是一家临床阶段的生物制药公司，为患有急性大麻素中毒和药物滥用疾病的人开发新的解决方案。其主要候选产品ANEB-001已完成2期临床试验（www.clinicaltrials.gov/ct2/show/NCT05282797）的剂量评估，评估其在阻断和逆转急性大麻素中毒的负面影响方面的效用。

ANEB-001 is a competitive antagonist at the human cannabinoid receptor type 1 (CB1). For further information about Anebulo, please visit www.anebulo.com..

ANEB-001是人类大麻素受体1型（CB1）的竞争性拮抗剂。有关Anebulo的更多信息，请访问www.Anebulo.com。。

About ANEB-001

关于ANEB-001

Our lead product candidate is ANEB-001, a potent, small molecule cannabinoid receptor antagonist, under development to address the unmet medical need for a specific antidote for ACI. ANEB-001 is an orally bioavailable, readily absorbed treatment candidate that we anticipate will rapidly reverse key symptoms of ACI.

我们的主要候选产品是ANEB-001，一种有效的小分子大麻素受体拮抗剂，正在开发中，以解决ACI特定解毒剂未满足的医疗需求。ANEB-001是一种口服生物可利用，易于吸收的治疗候选药物，我们预计它将迅速逆转ACI的关键症状。

ANEB-001 is protected by one issued patent and rights to one patent application covering various methods of use of the compound and delivery systems. We are targeting initiation of Phase 3 registrational studies of ANEB-001 in the first half of 2024. In addition, an observational study in patients presenting to Emergency Departments with ACI is currently ongoing.

ANEB-001受一项已发布专利和一项专利申请的权利的保护，该专利申请涵盖化合物和递送系统的各种使用方法。我们的目标是在2024年上半年启动ANEB-001的3期注册研究。此外，目前正在对急诊科ACI患者进行观察性研究。

The study will determine concentrations of cannabinoids and metabolites in plasma and gather information on signs and symptoms, patients’ disposition and selected subjective assessments..

该研究将确定血浆中大麻素和代谢物的浓度，并收集有关体征和症状，患者处置和选定主观评估的信息。。

Forward-Looking Statements

前瞻性声明

Statements contained in this press release that are not statements of historical fact are forward-looking statements as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, these forward-looking statements can be identified by words such as 'anticipate,' 'designed,' 'expect,' 'may,' 'will,' 'should' and other comparable terms.

本新闻稿中包含的非历史事实陈述是1933年“证券法”第27A条（经修订）和1934年“证券交易所法”第21E条（经修订）中定义的前瞻性陈述。在某些情况下，这些前瞻性陈述可以用“预期”，“设计”，“期望”，“可能”，“将会”，“应该”和其他可比较的术语来标识。

Forward-looking statements include statements regarding Anebulo's intentions, beliefs, projections, outlook, analyses or current expectations regarding: the anticipated initiation of phase 3 registrational studies of ANEB-001 in the first half of 2024; the potential for ANEB-001 to address an unmet medical need for a specific antidote for ACI; the determinations or outcomes of the ongoing observational study of ANEB-001; and Anebulo's expectation that ANEB-001 will rapidly reverse key symptoms of ACI.

前瞻性陈述包括关于Anebulo的意图，信念，预测，前景，分析或当前期望的陈述：预计在2024年上半年开始ANEB-001的3期注册研究；ANEB-001有可能解决ACI特定解毒剂未满足的医疗需求；正在进行的ANEB-001观察性研究的确定或结果；和Anebulo期望ANEB-001将迅速逆转ACI的关键症状。

You are cautioned that any such forward-looking statements are not guarantees of future performance and are subject to a number of risks, uncertainties and assumptions, including, but not limited to: initial and interim results from clinical studies are not necessarily indicative of results that may be observed in the future; the ability to obtain regulatory approval; the timing and success of clinical trials and potential safety and other complications thereof; any negative effects on Anebulo’s business and product development plans caused by or associated with health crises or geopolitical issues; and Anebulo's need for additional capital.

您需要警惕的是，任何此类前瞻性陈述均不能保证未来的表现，并且存在多种风险，不确定性和假设，包括但不限于：临床研究的初始和中期结果不一定表示结果可能会在未来观察到；获得监管部门批准的能力；临床试验的时机和成功及其潜在的安全性和其他并发症；对健康危机或地缘政治问题引起或与之相关的Anebulo业务和产品开发计划的任何负面影响；和Anebulo需要额外的资金。

These and other risks are described under the 'Risk Factors' heading of Anebulo's Annual Report on Form 10-K for the fiscal year ended June 30, 2023, as filed with the SEC on September 22, 2023. All forward-looking sta.

这些和其他风险在2023年9月22日提交给SEC的2023年6月30日结束财政年度Anebulo年度报告表格10-K的“风险因素”标题下描述。所有前瞻性的sta。